Direct-to-consumer prescription drug advertising and the public
- 159 Downloads
OBJECTIVE: Drug manufacturers are intensely promoting their products directly to consumers, but the impact has not been widely studied. Consumers’ awareness and understanding of, attitudes toward, and susceptibility to direct-to-consumer (DTC) drug advertising were examined.
DESIGN: Random-digit dialing telephone survey with a random household member selection procedure (completion and response rates, 58% and 69%, respectively).
SETTING: Respondents were interviewed while they were at their residences.
PARTICIPANTS: Complete data were obtained from 329 adults in Sacramento County, California.
MEASUREMENTS AND MAIN RESULTS: Outcome measures included awareness of advertisements for 10 selected drugs, misconceptions about DTC advertising, attitudes toward DTC ads, and behavioral responses to such promotions. The influence of demographic characteristics, health status, attitudes, beliefs, and media exposure on awareness and behaviors was examined. On average, respondents were aware of advertisements for 3.7 of the 10 drugs; awareness varied from 8% for Buspar (buspirone) to 72% for Claritin (loratadine). Awareness was associated with prescription drug use, media exposure, positive attitudes toward DTC advertising, poorer health, and insurance status. Substantial misconceptions were revealed; e.g., 43% thought that only “completely safe” drugs could be advertised. Direct-to-consumer advertisements had led one third of respondents to ask their physicians for drug information and one fifth to request a prescription.
CONCLUSIONS: Direct-to-consumer advertisements are reaching the public, but selectively so, and affecting their behaviors. Implications for public policy are examined.
Key Wordsprescription drugs advertising drug safety drug promotion drug regulation
Unable to display preview. Download preview PDF.
- 3.Jaklevic MC. Prescribed cutback: HMOs shift risk to doc groups to curb drug utilization. Mod Healthcare. 1997;27(29):34.Google Scholar
- 4.Growth seen in ads for direct-to-consumer drugs. Am Med News. April 27, 1998:16.Google Scholar
- 5.’t Hoen E. Direct-to-consumer advertising: for better profits or for better health? Am J Health-System Pharmacy. 1998;55:594–7.Google Scholar
- 6.Alperstein NM, Peyrot M. Consumer awareness of prescription drug advertising. J Advertising Res. 1993;33(4):50–6.Google Scholar
- 7.Rogers EM. Diffusion of Innovations. 3rd ed. New York, NY: The Free Press; 1983:241–70.Google Scholar
- 12.Carmines EG, Zeller RA. Reliability and Validity Assessment. Newbury Park, Calif: Sage; 1979.Google Scholar
- 13.Ware JE Jr. SF-36 Health Survey: Manual And Interpretation. Boston, Mass: The Health Institute, New England Medical Center; 1993.Google Scholar
- 14.Bentler PM, Wu EJC. EQS for Windows Users Guide. Encino, Calif: Multivariate Software, Inc.; 1995.Google Scholar
- 15.Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley; 1989.Google Scholar
- 16.Everett SE. Lay audience response to prescription drug advertising. J Advertising Res. 1991;31(2):43–9.Google Scholar
- 18.O’Keefe DJ. Persuasion: Theory and Research. Newbury Park, Calif: Sage; 1990.Google Scholar
- 19.Morris LA, Brinberg D, Klimberg R, Rivera C, Millstein LG. Miscomprehension rates for prescription drug advertisements. Curr Issues Res Advertising. 1986;9(1,2):93–117.Google Scholar